Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether empagliflozin, a medication in a
class known as sodium-glucose cotransporter-2 inhibitors (SGLT2) inhibitors, may reduce
symptoms of depression. Since this medication helps the body make metabolites known as ketone
bodies which can serve as an alternate energy source for the brain, the investigators can
also test whether ketone bodies help with depressed mood.